Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Double Blind, Randomized, Parallel-Group, Single-Dose, 3-Arm, Comparative Pharmacokinetic Study Of PF-06410293 and Adalimumab Sourced From US And EU Administered To Healthy Subjects

NCT01870986 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01870986
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01870986 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Double Blind, Randomized, Parallel-Group, Single-Dose, 3-Arm, Comparative Pharmacokinetic Study Of PF-06410293 and Adalimumab Sourced From US And EU Administered To Healthy Subjects
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2013
Completion date
February 28, 2014
Enrollment
210 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy